Under the 5-year, Indefinite Delivery/Indefinite Quantity contract with a potential value of up to $100 million, MRIGlobal will support BARDA’s mission to develop medical countermeasures and supportive reagents and assays against chemical threat agents for regulatory acceptance in the U.S.
“MRIGlobal has a rich history of providing innovative science and technology solutions to BARDA and we are honored to continue our support,” said Thomas M. Sack, Ph.D., President and Chief Executive Officer of MRIGlobal.
“This contract award shows that BARDA recognizes MRIGlobal as a key partner to accomplish chemical medical defense research goals,” said Robert P. Casillas, Ph.D., who will be serving as MRIGlobal’s Chief Scientific Officer for the contract.
Task Orders awarded to MRIGlobal will be funded entirely with Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Contract No. HHSO100201500003I.